First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol.22(24), 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Socinski MA, Crowell R, Hensing TE et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest132(3 Suppl.), S277–S289 (2007).
   PubMedGoogle Scholar
• Waters JS, O’Brien MER. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br. J. Cancer87(5), 481–490 (2002).
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol.19(13), 3210–3218 (2001).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum based doublets in advanced non small cell lung cancer. J. Clin. Oncol.20(21), 4285–4291 (2002).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani C et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, Von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations vs vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J. Clin. Oncol.21(16), 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Smit EF, Van Meerbeeck J, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer (NSCLC): a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Group-EORTC 08975. J. Clin. Oncol.21(21), 3909–3917 (2003).
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K et al. Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann. Oncol.18(2), 317–323 (2007).
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patients data meta-analysis. J. Natl Cancer Inst.99(11), 847–857 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer. A literature review. J. Thorac. Oncol.3(12), 1468–1481 (2008).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France (2004).
   Google Scholar
• Gabrielson E. Worldwide trends in lung cancer pathology. Respirology11(5), 533–538 (2006).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357(9267), 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Moran CA. Pulmonary adenocarcinoma: the expanding spectrum of histologic variants. Arch. Pathol. Lab. Med.130(7), 958–962 (2006).
   PubMedGoogle Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers – a different disease. Nat. Rev. Cancer7(10), 778–790 (2007).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med.358(11), 1160–1174 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.21(12), 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA290(16), 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with Erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol.22(16), 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Langer CJ et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer41(Suppl. 1), S29–S42 (2003).
   Web of Science ®Google Scholar
• Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol.23(14), 3227–3334 (2005).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J. Natl Cancer Inst.97(9), 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Peterson P, Park K, Fossella F et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a Phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2–6 September 2007. J. Thorac. Oncol.2(8 Suppl. 4), S851 (2007).
   Google Scholar
• Ohe Y, Ichinose Y, Nakagawa K et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin. Cancer Res.14(13), 4206–4212 (2008).
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Belani C et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a Phase III study. Presented at: 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8011).
   PubMedGoogle Scholar
• Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist6(4), 363–373 (2001).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer92(3), 595–600 (2001).
   PubMed Web of Science ®Google Scholar
• Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann. Oncol.11(4), 435–440 (2000).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin. Cancer Res.11(2 Pt 1), 690–696 (2005).
   PubMed Web of Science ®Google Scholar
• Zinner RG, Fossella FV, Gladish GW et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non small cell lung cancer. Cancer104(11), 2449–2456 (2005).
   PubMed Web of Science ®Google Scholar
• Belani CP, Brodowicz T, Peterson P, John W, Scagliotti GV. Non-squamous histology: a predictor of efficacy for pemetrexed treatment of non-small cell lung cancer (NSCLC). An analysis of Phase III trials using treatment-by-histology interactions. Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology 2008. Chicago, IL, USA, 13–15 November 2008. J. Thorac. Oncol.3(11 Suppl. 4), S266 (2008) (Abstract 10).
   Google Scholar
• Alimta package insert. Eli Lilly & Co., Indianapolis, IN, USA (2008).
   Google Scholar
• Alimta package insert. Lilly France SAS, Fegersheim, France (2008).
   Google Scholar
• Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer107(7), 1589–1596 (2006).
   PubMed Web of Science ®Google Scholar
• Sigmond J, Backus HH, Wouters D et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem. Pharmacol.66(3), 431–438 (2003).
   PubMedGoogle Scholar
• Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol.68(1), 110–118 (2005).
   PubMed Web of Science ®Google Scholar
• Huang C, Liu D, Nakano J et al. E2F-1 overexpression associated with TS and surviving gene expressions in non-small-cell lung cancer. Presented at: 2007 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007. J. Clin. Oncol.25(Suppl.) (2007) (Abstract 7669).
   Google Scholar
• Salon C, Merdzhanova G, Brambilla C Brambilla E, Gazzeri S, Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene26(48), 6927–6936 (2007).
   PubMed Web of Science ®Google Scholar
• Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J. Clin. Oncol.26(21), 3485–3486 (2008).
   PubMedGoogle Scholar
• Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist12(10), 1183–1193 (2007).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small cell lung cancer: AVAiL. J. Clin. Oncol.27, DOI: 10.1200/JCO.2007.14.5466 (2009) (Epub ahead of print)
   Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Reck M, Crinò L. Advances in anti-VEGF and anti-EGFR therapy in advanced non-small cell lung cancer. Lung Cancer63(1), 1–9 (2009).
   PubMedGoogle Scholar
• Sandler A, Kong G, Strickland D, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). Presented at: Chicago Multidisciplinary Symposium In Thoracic Oncology 2008. Chicago, IL, USA, 13–15 November 2008. J. Thorac. Oncol.3(11 Suppl. 4), S283 (2008) (Abstract 133).
   PubMedGoogle Scholar
• Reck M, von Pawel J, Zatloukal P et al. First-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): AVAiL (BO17704), a Phase III randomized study. Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology 2008. Chicago, IL, USA, 13–15 November 2008. J. Thorac. Oncol.3(11 Suppl. 4), S302; LBA (2008).
   Google Scholar
• Shaked Y, Henke E, Roodhart JML et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell14(3), 263–273 (2008).
   PubMed Web of Science ®Google Scholar
• Hainsworth J, Compton P, Strickland D, Azzoli CG. BRIDGE: an open-label Phase II evaluating the safety of bevacizumab (BV) + paclitaxel/carboplatin (PC) as 1st-line treatment for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology 2008. Chicago, IL, USA, 13–15 November 2008. J. Thorac. Oncol.3(11 Suppl. 4), S281 (2008) (Abstract 128).
   Google Scholar
• Akerley WL, Langer CJ, Oh Y et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. Presented at: 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8043).
   PubMedGoogle Scholar
• Dalsania CJ, Hageboutros A, Harris E, Krieger K, Vora C, Stevenson J. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced non-squamous non-small cell lung cancer. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007. J. Clin. Oncol.25(Suppl.) (2007) (Abstract 18163).
   Google Scholar
• Patel JD, Hensing TA, Rademaker F et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May –2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8044).
   Google Scholar
• Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch. Pathol. Lab. Med.131(7), 1027–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Travis WD, Garg K, Franklin WA et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J. Clin. Oncol.23(14), 3279–3287 (2005).
   PubMed Web of Science ®Google Scholar
• Kris MG, Giaccone G, Davies A et al. Systemic therapy of bronchioloalveolar carcinoma: results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. J. Thorac. Oncol.1(9 Suppl.), S32–S36 (2006).
   Google Scholar
• Garver RI Jr, Zorn GL, Wu X, McGiffin DC, Young KR Jr, Pinkard NB. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N. Engl. J. Med.340(14), 1071–1074 (1999).
   PubMedGoogle Scholar
• West HL, Crowley JJ, Vance RB et al. Advanced bronchioloalveolar carcinoma: a Phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). Ann. Oncol.16(7), 1076–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Smit E, Bosquee L et al. A Phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer50(1), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• West HL, Franklin WA, McCoy J et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group (SWOG) study S0126. J. Clin. Oncol.24(12), 1807–1813 (2006).
   PubMed Web of Science ®Google Scholar
• Kris MG, Sandler A, Miller V et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a Phase II trial in patients with bronchioloalveolar carcinoma (BAC). Presented at: 2004 American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA, 5–8 June 2004. J. Clin. Oncol.22(Suppl.) (2004) (Abstract 7062).
   PubMedGoogle Scholar
• Strauss GM, Jemal A, McKenna MB et al. Creation of an epidemic: The tobacco industry (TI) and smoking-related adenocarcinoma (AD) of the lung. Presented at: 2007 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007. J. Clin. Oncol.25(Suppl.) (2007) (Abstract 7583).
   PubMedGoogle Scholar
• Karp DD, Paz-Ares LG, Novello S et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. Presented at: 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8015).
   PubMedGoogle Scholar
• Gualberto A, Melvin CL, Dean A et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. Presented at: 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 8000).
   PubMedGoogle Scholar
• Mendelsohn J. Epidermal growth factor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res.3(12 Pt 2), 2703–2707 (1997).
   PubMed Web of Science ®Google Scholar
• Raben D, Helfrich B, Chan DC et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res.11(2 Pt 1), 795–805 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L et al. A randomized multicenter Phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2–6 September 2007. J. Thorac. Oncol.2(8 Suppl. 4) (2007) (Abstract B3-03).
   Google Scholar
• Pirker R, Szczesna S, von Powel J et al. FLEX: A randomized, multicenter, Phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). Presented at: 2008 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May–2 June 2008. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 3).
   PubMedGoogle Scholar
• Tsuchihashi Z, Khambata-Ford S, Hanna N et al. Responsiveness to cetuximab without mutation in EGFR. N. Engl. J. Med.353(2), 208–209 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Herbst RS, Olsen C et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J. Clin. Oncol.26(20), 3351–3357 (2008).
   PubMed Web of Science ®Google Scholar